Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)

The summary for the Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) encourages SBIR grant applications from small businesses to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next three to five years.

Federal Grant Title:	Novel Genomic Technology Development (R43/R44 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-18-779
Type of Funding:	Grant
CFDA Numbers:	93.172
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 7th, 2021
Original Application Deadline:	January 7th, 2021
Posted Date:	May 9th, 2018
Creation Date:	May 9th, 2018
Archive Date:	February 12th, 2021
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	May 9th, 2018

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-18-779.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed); • Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed); • NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed); • Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Op...; • Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult ...; • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44); • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42); • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...